Shots:

• Elanco acquires Bayer’s animal health business in cash & stock transaction- making a total deal value $7.6B. Bayer to get $5.32B cash as up front and $2.28B/~68M as Elanco’s common share with the expected closure of transaction in mid-2020
• The focus of the acquisition is to strengthen & accelerating Elanco’s IPP strategy through a pipeline- delivery platforms- scale and access to Bayer R&D- making Elanco second largest animal health leader by revenue across the globe
• The agreement will double Elanco’s pet business with brands balancing Food Animal/Companion Animal mix and will combine Elanco’s veterinary focus with Bayer’s e-commerce and retail leadership- enhancing the merging market presence thus strengthening the cattle business

Click here to­ read full press release/ article | Ref: Elanco | Image: Display Studios